Recently a new linker -hydrazinonicotinate (HYNIC) -was introduced for labelling of proteins and peptides with technetium-99m. HYNIC and other linkers have been used for labelling of human non-specific polyclonal immunoglobulin G (hlgG) with 99mTc for the detection of infections. In this study we compared the tissue distribution of three different 99mTc-hIgG preparations in groups of five Wistar rats with a focal intramuscular infection with Staphylococcus aureus. We compared 99mTc-HYNIC-hlgG with 99mTc-hIgG labelled via the so-called Schwarz method (reduction of disulphide bonds) and with the 99mTc-labelled commercially available Technescan-HIG. Unlike the HYNIC linker, in the two other labelling methods free sulph-hydryl groups are involved in the binding of 99mWc. High-performance liquid chromatography analysis of the labelled preparations and of plasma samples revealed aggregate or polymer formation in all three agents; this was least pronounced in the product labelled by means of the Schwarz method. The tested preparations did not show signs of degradation in vitro. The difference in linker chemistry was reflected in the tissue distribution. Thus the biodistribution of 99mTc-HYNIC-hlgG was significantly different from the distribution of the two other preparations: abscess (1.4%+0.2%ID/g), muscle, liver, spleen, plasma, lung, bone marrow, and small intestine concentrations were higher at 24 h p.i.; kidney uptake (1.19%+O.08%IDIg) was significantly lower. The abscess-to-plasma and the abscess-to-muscle ratios (0.5 and 11, respectively), however, were in the same range for the three preparations tested. Quantitative analysis of the scintigraphs revealed that the total body clearance of 99mTc-HYNIC-hlgG was significantly slower than for the other agents. The abscess uptake of 99rnTc-HYNIC-hlgG as a percentage of the remaining body activity was significantly higher. Based on its high abscess uptake, its low uptake in the kidneys and the high percentage of its abscess uptake in Correspondence to: R.A.M.J. Claessens relation to the remaining body activity, we conclude that 99mTc-HYNIC-hlgG seems superior to the two other preparations tested for the detection of infections.
Introduction
Indium-ill labelled human non-specific polyclonal immunoglobulin G (lllIn-hIgG) has been proposed for the detection of inflammatory and infectious lesions [1] . This agent has proved to be clinically useful in a variety of infectious diseases and is often superior to conventional agents like labelled leucocytes and gallium-67 citrate [2] [3] [4] [5] [6] [7] . Despite the positive characteristics of l llInhIgG, the use of l tlIn has a few inherent disadvantages. l llIn is expensive, not always available and causes a relatively high radiation burden to patients, and its gamma radiation is suboptimal for scintigraphy. Technetium99m would be a more attractive alternative. However, ' . our first experiences with 99mTc-hIgG (using 2-iminothiolane derivatized hlgG) have been inferior as compared with 11 qn-hIgG [8] .
Recently, Abrams et al. introduced a new method for labelling of proteins with 99mTc [9, 10] . Their study showed that 99mTc-hIgG labelled via hydrazinicotinate (HYNIC) performs similarly to 111In-hlgG in detecting infections in rats. To evaluate the new agent, we compared the tissue distribution and the uptake in infections in rats of 99mTc-HYNIC-hIgG and 99mTc-hIgG labelled with technetium-99m according to a modification of the so-called Schwarz method [11] . In addition, we included in this comparative study for reference purposes 99mTc-hIgG prepared by reconstitution of a commercially avail-able Technescan-HIG kit (Mallinckrodt Medical, Petten, The Netherlands).
Materials and methods

Radiopharmaceuticals
99mTc-HYNIC-IgG. Succinimidyl 6-hydrazinopyridine-3-carboxylate hydrochloride was synthesized as described by Abrams et al. [9] with some minor modifications in the purification and final deprotection of the N-BOC-protected precursor. Briefly, succinimidyl 6-BOC-hydrazinopyridine-3-carboxylic acid was purified by chromatography on silica gel 60 (230400 mesh ASTM, E. Merck, Darmstadt, Germany) using ethyl acetate as an eluent. The eluate was concentrated to dryness; the residue was recrystatlized from 20% ethyl acetate in hexane. Succinimidyl 6-hydrazinopyridine-3-carboxylate hydrochloride was prepared as follows: 100 mg of succinimidyl 6-BOC-hydrazinopyridine-3-carboxylic acid was dissolved in 1 ml acetic acid and 2 ml of a saturated solution of hydrogen chloride gas in acetic acid was added. After stirring for 1 h, diethyl ether was added until a white precipitate was formed. The settled precipitate was washed 4 times with diethyl ether and dried under high vacuum. This product was used as such. Hydrogen-1 nuclear magnetic resonance (NMR) spectroscopy and elemental analysis were performed at the Department for Organic Chemistry of the University of Nijmegen.
Human non-specific polyclonal immunoglobulin G was conjugated to 6-hydrazinopyridine-3-carboxylate (6-hydrazino-3-nicotinate) as follows: Lyophilized hIgG (539 rag; Baxter/Hyland Gammagard S/D, Lessines, Belgium) was dissolved in 5 ml sterile pyrogen-free water. The solution was dialysed overnight at 4°C against phosphate-buffered saline (pH=7.4; PBS) to remove lowmolecular-mass additives. The dialysed hlgG solution was filtered over a sterile 0.22-gm filter (Millipore Millex-GV SLGV 025 BS, Molsheim, France) and collected in a sterile vial for injection fluids. To 2.5 ml of this filtered hIgG solution, 0.25 ml 1 M sodium hydrogen carbonate solution (pH=8.2) was added. While stirring, ten portions of 10 gl of a succinimidyl-6-hydrazinopyridine-3-carboxylate hydrochloride solution (6 mg/ml in dry dimethyl sulphoxide) were added to the alkaline hlgG solution at 3-min intervals (HYNIC/hIgG ratio=2.5). After incubation at room temperature for 30 min the mixture was cooled in an ice bath and 3 ml cold 0.15 M sodium acetate buffer (pH=5.85) was added. The HYNIChIgG solution was dialysed overnight at 4°C against 0.15 M sodium acetate buffer (pH=5.85). The dialysed HYNIC-hIgG solution was filtered over a sterile 0.22-gm filter and collected in a sterile vial for injection fluids. The protein concentration, as estimated with the Bio-Rad protein assay (Bio-Rad laboratories, Mtinchen, Germany), was adjusted to 4 mg/ml by adding sterile 0.15 M sodium acetate buffer (pH=5.85). The number of HYNIC groups per IgG molecule was determined by measuring the optical density at 385 nm of the hydrazone (extinction coefficient: 2.53x104 1.mol-l-cm -~) resulting from the reaction of protein-conjugated hydrazino groups with p-nitrobenzaldehyde [12] . The HY-NIC-conjugated hIgG solution was stored under argon gas at -20°C in portions of 0.5 ml (2 mg).
For labelling of HYNIC-hIgG with 99mTc, tricine [N-(tris(hydroxymethyl)methyl)glycine, Fluka Chemika, Buchs, Switzerland] was used as an intermediary ligand as described by Larsen et al. [13] . A volume of 5 rnl of saline was added to a vial containing sterile lyophilized stannous sulphate (1 mg) and tricine (10 rag) under argon gas. From this vial 50 gl was taken and add-ed to a vial containing 2 mg HYNIC-hIgG. Then, 1480 MBq 99mTc-pertechnetate in approximately 1 ml saline was added. The mixture was incubated at room temperature for 15 rain. The product, 99mTc-HYNIC-hIgG, containing approximately 2 mg hIgG, was diluted to 5 ml with saline and used as such, provided that the amount of pertechnetate was less than 10%.
99mTc-hlgG labelled according to a modification of the Schwarz method. In 1987, Schwarz and Steinstr~isser in an abstract described a new approach to labelling of monoclonal antibodies with 99mTc [11] . Although the method has not been described in detail by these authors, it is referred to in the literature as the Schwarz method. A more in-depth treatment of this method is given by Mather and Ellison [14] . We used a different reducing agent and a different intermediary ligand as compared to the original method. To 0.3 ml of the dialysed and filtered hIgG solution (see above), 60 gl of a freshly prepared dithioerythritol solution (DTE, Sigma Chemical Company, St. Louis, Mo.; 2 mg in 2 mt 0.1 M tris buffer, pH=9) was added. The mixture was incubated for 20 min at room temperature. Contaminants of low molecular mass were removed by get filtration on a PD-10 column (Pharmacia Biotech AB, Uppsala, Sweden) using PBS as eluent. The protein fractions were pooled, filtered over a sterile 0.22-gm filter and collected in a sterile vial for injection fluids. The protein concentration was estimated using the Bio-Rad protein assay. The reduced hIgG solution was stored under argon gas at -20°C in 1-mg portions. The number of free sulph-hydryl groups per molecule of IgG was estimated using Ellman's reagent (Sigma Chemical Company, St. Louis, Mo.) [15] .
For labelling of DTE-reduced hIgG with 99mTc, tricine was used as an intermediary ligand, as described for labelling of HY-NIC-hlgG. The radiolabelled product, containing approximately 1 mg hIgG, was purified by gel chromatography on a PD-10 column with PBS as eluent. The protein fractions were pooled and the volume was adjusted to 5 ml with saline.
99'nTc-Technescan-HIG.
A Technescan HIG labelling vial (Mallinckrodt Medical, Petten, The Netherlands), containing 1 mg hIgG and 8 gg stannous tin, was reconstituted with 740 MBq 99mTc-pertechnetate according to the manufacturer's instructions. The labelled product was diluted to 5 ml with saline and used as such.
Radiochemical purity. The radiochemical purity of the three 99mTc-labelled hIgG preparations was determined by instant thinlayer chromatography (ITLC) on Gelman ITLC-SG strips (Gelman Laboratories, Ann Arbor, Mich.) with 0.15 M sodium acetate buffer (pH=6.5) as solvent.
In addition to ITLC, samples of the three 99rnTc-hIgG preparations were analysed by size exclusion high-performance liquid chromatography (HPLC) using a PROTEIN PAK 300 SW column (7.8 mmx300 mm; Millipore-Waters, Milford, Mass.) and PBS as mobile phase (flow rate 1.0 ml/min). In size exclusion liquid chromatography, molecules are eluted in order of decreasing size. The eluate was monitored by measurement of the optical density at 280 nm (OD280) (Millipore-Waters, Milford, Mass.) and by measurement of the radioactivity (Radiomatic, Tampa, F1.). In addition, a diluted sample of untreated hIgG from the batch used for labelling was analysed by HPLC.
In vittv stability. The in vitro stability of 99rnTc-HYNIC-hlgG and 99mTc-hIgG labelled according to the Schwarz method was estimated by HPLC analysis of samples of each of the labelled proteins 1:3 diluted in PBS or rat plasma, respectively, and incubated at 37°C for 24 h.
AU
Infection model and tissue distribution study
After ether anaesthesia a calf muscle abscess was induced in young, male, randomly bred Wistar rats (body mass 200-220 g) with approximately 2x108 colony-forming units of Staphylococcus aureus suspended in 0.1 ml of a 1:1 mixture of autologous blood and saline. The animals were randomly divided into groups of five. Twenty-four hours after inoculation of S. aureus in the muscle, when swelling of the muscle was apparent, 0.2 ml of a solution of one of the three radiopharmaceuticals was injected in the tail vein. The protein dose per rat was 10 ~tg; the 99mTc dose was 12 MBq per rat.
To collect tissues, rats were killed with 30 mg intraperitoneally injected phenobarbital, followed by cervical dislocation at 2, 8 or 24 h after injection of the radiopharmaceutical. All three radiopharmaceuticals were evaluated in five animals at each time point. Samples of bone marrow (taken from the right femur), blood and urine were collected. Tissues (infected left calf muscle, right calf muscle, liver, spleen, kidney, lung, duodenum, and right femur) were dissected, blotted dry and weighed. Blood, collected in a heparinized tube, was centrifuged and a plasma sample was taken and weighed. Plasma and urine samples taken at 7 h after injection of 99mTc-hIgG were analysed by HPLC, as described above.
The radioactivity in the tissues and samples was measured in a shielded well-type gamma counter. To correct for radioactive decay and permit calculation of the uptake of the radiopharmaceuticals in each organ as a fraction of the administered dose, aliquots of the respective doses were counted simultaneously. The measured activity in tissues and samples was expressed as percentage of injected dose per gram.
Scintigraphic imaging
A separate set of rats (three rats per radiopharmaceutical) with the same infection as described for the biodistribution study were intravenously injected with 12 MBq of one of the three 99mTc-hIgG (10 gg hIgG) preparations. Scintigraphic images were obtained with a Siemens Orbiter gamma camera connected to a Scintiview image processor and an Icon computer system (Siemens Inc., Hoffman Estates, Ill.). All images were acquired in a 256x256 matrix. A low-energy general-purpose parallel hole collimator was used with a 15% symmetric window around the 140-keV 99mTc gamma peak. Images were acquired at 5 rain and 1, 2, 4, 6, 12 and 24 h after injection of the respective radiopharmaceutical with a preset number of 300 kcounts. The time needed to collect 300 kcounts was noted. Regions of interest were drawn for heart, the infection focus, the normal contralateral calf muscle and the whole rat body. The whole-body activity at 5 min post injection (p.i.) was set at 100%. During imaging the rats were anaesthetized with a mixture of oxygen gas (500 ml/min)/nitrous oxide gas (300 ml/min) and halothane.
Statistical analysis
Mean values are given + the standard deviations (SD). Significance was set at 0.05 (two-sided). Before carrying out the statistical testing, all measured values were log-transformed in order to obtain homoscedasticity (log-normal distribution). On these logtransformed data from samples taken at 24 h p.i. a one-way AN-OVA test was performed. In order to evaluate the significance of the differences between the three 99mTc-labelled hIgG preparations, Bonferroni-corrected P values were calculated for each pair of radiopharmaceuticals in the study. The average number of HYNIC groups per hIgG molecule was 2.4. ITLC analysis of the reaction product after labelling of HYNIC-hIgG with 99mTc demonstrated a radiochemical purity of higher than 98%. Figure 1A shows the OD280 profile for unprocessed hlgG from the same batch as was used for the labelling procedures of HYNIC-hIgG and Schwarz-hIgG. The radioactivity profile of HPLC analysis of the freshly labelled 99mTc-HY- 99mTc-hIgG (Schwarz) . The average number of free sulph-hydryl groups per hIgG molecule after reduction with DTE was 1.6. ITLC analysis after labelling of DTE-reduced hIgG with 99mTc revealed a labelling efficiency slightly less than 90%. After purification of the reaction product by gel filtration, a radiochemical purity of more than 98% was found. The radioactivity profile of HPLC analysis immediately after labelling and purification is shown in Fig. 1C . Figure 2B presents the radioactivity profile of 99mTc-hIgG (Schwarz) after 24-h incubation in vitro in rat plasma at 37°C.
99"Tc-Technescan-HIG.
The amount of pertechnetate, as determined by ITLC, was 3%. Figure lD shows a radio-HPLC profile of 99mTc-Technescan-HIG immediately after labelling.
In vitro stability testing of 99mTc-HYNIC-hIgG and 99mTc-Schwarz-hIgG in rat plasma (Fig. 2) showed formation of only small amounts of degradation products of low molecular mass. 99mTc-HYNIC-hIgG showed more polymer or aggregate formation after incubation in rat plasma in vitro than did 99mTc-Schwarz-hlgG. Figure 3 presents the HPLC radioactivity profiles for plasma samples taken at 7 h after injection of each of the three 99mTc-hIgG preparations. HPLC analysis shows an appreciable amount of polymer or aggregate formation for HYNIC-hIgG (Fig. 3A) . As in the freshly labelled . Abscess-to-plasma ratio versus time is shown in E and abscess-to-muscle ratio versus time in F. Experiments were performed in male Wistar rats (five rats per time point) preparations ( Fig. 1) , Schwarz-hIgG has less polymer formation than Technescan-HIG, possibly related to the difference in the number of free sulph-hydryl groups in these two agents. Figure 4 presents the HPLC radioactivity profiles for urine samples taken at 7 h after injection of each of the three 99mTc-hIgG preparations. The three profiles show a similar pattern in agreement with urinary Significance: P<0.05; NS, non-significant excretion of 99mTc-labelled species of low molecular mass. Figure 5 shows the radioactivity concentration in abscess (5A), muscle (5B), plasma (5C), and kidney (5D) for each of the three 99mTc-hIgG preparations at three time points after injection. In contrast to the abscess uptake of Schwarz-hlgG and Technescan-HIG, the abscess uptake of 99mTc-HYNIC-hlgG increases over time (Fig. 5A) . Figure 5E shows the abscess/plasma activity ratios and Fig. 5F presents the abscess/muscle activity ratios for the three agents under study at 2, 8 and 24 h after injection. Despite the differences in the tissue distributions, the ratios shown in Figs 5E and 5F are similar for the three agents tested. Table 1 presents the distribution data for the three 99mTc-hIgG preparations at three time points after injection for tissues not shown in Fig. 5 . The difference in the coordination chemistry of the 99mTc-labelled proteins in this study is reflected in the tissue distribution results (Fig. 5 , Table 1 ). 99mTc-HYNIC-hlgG behaves in a significantly different way from the other preparations (see Fig. 5 and Tables 1 and 2 ). At 24 h p.i. the 99mTc uptake in abscess, muscle, plasma, liver, spleen, lung, bone marrow and small intestine obtained with 99mTc-HYNIC-hlgG is significantly higher than that obtained with the other two agents. In contrast, the kidney uptake of 99mTc-HYNIC-hIgG is significantly lower than that of the other preparations (see Fig. 5D ). Table 2 presents Bonferroni-corrected P values for the pairwise comparison of the activity uptake at 24 h p.i. in plasma and several tissues of the three 99mTc-hlgG preparations under study. Figure 6 shows scintigraphic images for groups of three rats at 12 h after injection for each of the three 99mTc-labelled hIgG preparations. In all rats the infections foci (Fig. 6B,  C) . By contrast, the kidney uptake with 99mTc-HYNIChIgG is remarkably low. The slow blood clearance of 99mTc-HYNIC-hIgG is reflected in the high activity in the heart (Fig. 6A) . Figure 7A shows the total body retention of radioactivity over time as a percentage of the activity at 5 min after injection for each of the three 99mTc-labelled hIgG preparations as determined by scintigraphy. The total body retention of 99mTc-HYNIC-hIgG is significantly higher than that of the other preparations from 4 h p.i. onwards. Figure 7B shows the abscess/total body activity ratio over time for each of the three labelled hIgG preparations. It is interesting to note that, despite the similar abscess-to-plasma and abscess-to-muscle ratios for the three 99mTc-hlgG preparations (Fig. 5E, F) , the abscess uptake of 99mTc-HYNIC-hIgG as a percentage of the remaining total body activity is significantly higher than the percentage for the other two agents (Fig. 7B) . So not only the absolute value of the uptake in infectious foci of 99mTc-HYNIC-hIgG is significantly higher than the abscess uptake of the other two agents, but also the proportion of the remaining body activity that is retained in the abscess is higher for 99mTc-HYNIC-hlgG.
HPLC analysis of plasma and urine samples
Biodistribution
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Discussion
The aim of this study was to evaluate the potential of the newly developed 99mTc-labelled HYNIC derivatized hIgG for the detection of infections in comparison with two other 99mTc-hlgG preparations. In addition to HY-NIC we introduced another commonly used linker (sulph-hydryl group generated using the Schwarz method) into hlgG of the same source (Baxter/Hyland). We selected this brand of hIgG because it gave the best resuits in terms of abscess uptake and tissue distribution in 419 a comparative study with four brands of hIgG (Baxter/Hyland, CLB, Miles, and Sandoz) and HYNIC as linker (E. Koenders, unpublished results). For comparative reasons we included Technescan-HIG from Mallinckrodt Medical, which is commercially available for the detection of inflammatory lesions. In the latter agent free sulph-hydryl groups on N-l-imino-4-mercaptobutylene side chains are introduced by reaction of hIgG with iminothiolane.
In our first experiments with HYNIC-hIgG we used glucoheptonate as intermediary ligand according to Abrams et al. [9] . Glucoheptonate, however, appeared suboptimal: it took many hours to obtain >80% labelling efficiency and in its presence the amount of stannous tin was rather critical: the greater the amount of tin, the slower the labelling reaction. The use of tricine as proposed by Larsen et al. [13] gave better labelling results: >95% labelling efficiency within less than 20 min under otherwise similar conditions.
The HPLC radioactivity profiles of the three 99mTc-labelled hIgG preparations (Fig. 1B-D) indicate that all 99mTc-labelled hIgG preparations contained some aggregates or polymers. The least polymeric contamination was observed for the so-called Schwarz hlgG (Fig. 1C) . Based on HPLC analysis of each individual step in the labelling process of hIgG, we conclude that aggregate or polymer formation is partly caused by the mere handling of the hIgG, i.e. keeping it for some time at elevated pH, with overnight dialysis. The major part of polymeric contamination, however, was formed as a result of the chelating agent used. Two of the three hIgG preparations in this study use free sulph-hydryl groups to bind technetium. Free sulph-hydryl groups are known to form disulphide bonds spontaneously, especially at pH=7.8 and above. This reaction is catalysed by traces of metal ions. Therefore, to stabilize solutions of Fab" fragments, small amounts of EDTA are added. To our preparations no EDTA was added. As stated above, the Schwarz-hIgG contained least polymeric contamination. An explanation of this phenomenon may be provided by the fact that in Schwarz-hIgG the average number of free sulphhydryl groups per molecule of protein is 1.6, whereas in iminothiolane-modified hlgG (Technescan-HIG) the average number of free sulph-hydryl groups is probably higher (this could not be determined with Ellman's reagent for Technescan-HIG because of the presence of stannous tin in the kit formulation). Moreover, in Schwarz-hIgG pairs of sulph-hydryl groups are in close proximity. Therefore, upon reoxidation in Schwarz-hIgG, formation of intramolecular disulphide bridges will probably prevail over intermolecular bond formation.
The HYNIC-modified hIgG also contained an appreciable amount of polymers or aggregates. A possible explanation for this is provided by the work of King et al. [12] . They showed that at concentrations as low as 10 btM acyl hydrazide-modified proteins react with aryl aldehyde-modified proteins, forming polymeric protein species. Phenyl hydrazines are known to form phenyl hydrazones after reaction with carbonyl functions in sugar molecules. IgGs are glycoproteins and contain sugar residues. The hydrazino groups might react with sugar molecules in the same or another protein molecule, thus forming cross-links and polymeric protein species. This possible explanation for the observation, illustrated by Figs. 1B, 2A and 3A, is supported by the fact that we found no or almost no polymer formation after modification of albumin (which does not contain sugar moieties) with HYNIC. The recent work of Verbeke and colleagues confirms the absence of polymeric species in the preparation formed after labelling of HY-NIC-HSA with 99mTc [16] .
HPLC analysis of plasma samples shows even less formation of degradation products of low molecular mass than HPLC analysis after incubation in rat plasma in vitro. Low-molecular-mass metabolites are rapidly excreted through the kidneys, as confirmed by HPLC analysis of urine samples (see Fig. 4) .
The low kidney uptake of 99mTc-HYNIC-hIgG is of importance with respect to the detection of intra-abdominal and retroperitoneal infectious loci. The relatively high renal uptake of the other two 99mTc-hIgG preparations is probably related to formation of small free sulph-hydryl-containing metabolites in the two agents using sulph-hydryl groups for coordination of technetium. This may be the result of protein catabolism or transchelation of technetium to cysteine or a cysteinelike molecule [17] . The second possibility seems more likely: it could be demonstrated by means of a double labelling experiment with 99mTc/14C-hIgG (with free sulph-hydryl groups for binding of technetium) in rats that the disappearance rate of 99mTc from plasma was faster than the plasma disappearance rate of 14C-hlgG. Moreover, in plasma formation of 99mTc-labelled material of low molecular mass was observed and a 99mTc-labelled species was found to be retained in the kidneys [18] . Molecules with free sulph-hydryl groups with or without 99mTc are known to be retained in the renal cortex. 14C-dimercaptosuccinic acid (DMSA) and 99mTc-DMSA are examples of such agents [19] . Metallothionein, a metal binding protein in the renal cortex with a cysteine content as high as 30%, is the binding site for metal ions like cadmium and zinc and probably also for mercury (Hg +) ions [20] . Metallothionein is supposed to bind not only metal ions, but also sulph-hydrylcontaining molecules like 14C-DMSA [21] . It has actually been demonstrated that 14C-DMSA and Hg + ions compete for the same binding site in the renal cortex [19] . After administration of 99mTc-labelled DMSA a 99mTc-labelled species has been proposed to be retained in the renal cortex after partial dissociation of the 99mTc-labelled complex [19] . The mechanism for renal binding of 99mTc-labelled DMSA could also explain the retention in the kidney of 99mTc-labelled cysteine or a cysteinelike molecule.
Despite the higher abscess uptake of 99mTc-HYNIChIgG, the abscess-to-plasma and the abscess-to-muscle ratios are similar for the three agents in this study (Fig. 5E, F) , suggesting that the higher uptake of 99mTc-HYNIC-hIgG in infections and most tissues is related to its slower plasma clearance. The latter might be explained by the relatively high in vivo stability of the 99mTc-HYNIC-hIgG preparation. The high and over time increasing abscess uptake of 99mTc-HYNIC-hIgG is probably not only related to its slow plasma clearance. In foci of infection 99mTc seems to be released from 99mTc-HYNIC-hIgG and retained locally [18] . The reason for this phenomenon is not yet known.
In conclusion: In this comparative study 99mTc-HY-NIC-hIgG had the highest abscess uptake, the lowest kidney uptake and the highest proportion of the remaining body activity that is retained in the abscess. In vivo in rats, 99mTc-HYNIC-hIgG behaved significantly differently from the other two 99mTc-hIgG preparations used in this study. This is a reflection of the differences in the chelating chemistries in these agents. Based on our results 99mTc-HYNIC-hIgG seems the superior agent for detection of infectious foci as compared to two other 99mTc-hIgG preparations.
